Ecrins Therapeutics

Entreprise
RESPONSABLECO-RESPONSABLE
Andreï Popov
andrei.popov@ecrins-therapeutics.com  
Aurélie Juhem
aurelie.juhem@ecrins-therapeutics.com

CHAMPS D’EXPERTISE

Ecrins Therapeutics is a clinical-stage privately held Biotech company specialized in the discovery and development of innovative oncology drugs

ACTIVITES DE RECHERCHE / SERVICES

Ecrins Therapeutics is a clinical-stage privately held Biotech company specialized in the discovery and development of innovative oncology drugs.

Using its original drug candidate discovery platform, Ecrins has created a pipeline of high-value projects.
Our main drug candidate ET-D5 is being developed for human and veterinary oncology applications and is currently in the regulatory preclinical phase (human oncology). Validating our approach, ET-D5 is already being tested in the canine clinical trial of patients suffering from high-grade sarcomas.

Two more innovating drug discovery programs (small molecules and therapeutic antibodies) are progressing rapidly towards pre-clinical development; their targets are unique and will be exploited for the treatment of cancer.

COMPETENCES/MOYENS TECHNIQUES

Incorporated in July 2010, Ecrins Therapeutics put in place an original and disruptive drug discovery platform allowing to discover and develop patentable molecules directed against new therapeutic targets. The founders of the company, experts in cell biology, live cell microscopy and biochemistry, have developed a unique concept based on the creation of cellular models of human cancer.
Indeed, instead of the endless search of molecules killing established cancer cell lines, we create cells with a well-defined cancer-related phenotype (physical trait). We then use these cell models of human cancer to find small molecules or biologicals (therapeutic antibodies) which can reverse the target cancer hallmark.
The discovery of bioactive molecules is followed by the identification of their targets and characterization of the mechanism of action (MOA). The proof-of-concept of this drug discovery platform has already been achieved through the development of the ET-D5 program. The scale-up of this approach is ongoing with two early-stage projects.

OU NOUS TROUVER ?

Biopolis- 5 avenue du Grand Sablon 38700 La Tronche

https://ecrins-therapeutics.com